A prostate cancer book that is uniquely useful
There is a large number of books for patients that deal with a diagnosis and management of prostate cancer. However, there is a relatively small number of books that are really valuable for a large...
View Article“The best” therapy for Gleason 10 prostate cancer
We recently saw (see this link) that men diagnosed with a Gleason score (GS) of 9 or 10 had lower rates of metastasis and better prostate-cancer survival if they were treated with a combination of...
View ArticleFDA approves use of enzalutamide (Xtandi) for nmCRPC
As we predicted just a couple of weeks ago, on Friday the US Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant...
View ArticleSpeed of change in the management of prostate cancer
One of our regular correspondents (who lives in England) was recently told something rather interesting by the Consultant Urologist he sees in the UK. The gist of the Consultant Urologist’s comment was...
View ArticleEarly data from the PROPS imaging trial prior to SRT
A recent presentation by Pouliot Frederick, MD, at the annual meeting of the Canadian Urological Association in Halifax, Nova Scotia, provided information on the roles of multiparametric MRI,...
View ArticleProstate cancer outcomes today vs. outcomes yesteryear
As some of us have long suspected and understood, using data from men treated 20+ years ago as a guide to what would happen if you were treated the same way today is not really a very good idea. A...
View ArticleThe “war” on cancer: are we “winning” or “losing” or what?
Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the...
View ArticleCan RP + EBRT + ADT provide equal outcomes to brachy boost therapy + ADT in...
As we have seen previously (see this link), among men with Gleason 9 or 10 disease, brachy boost therapy (BBT) provided better oncological outcomes compared to either radical prostatectomy (RP) alone...
View ArticleWhat patients think and understand can impact their decisions and their outcomes
It has long been appreciated that African-American males have higher risk for diagnosis with prostate cancer, and higher risk for prostate cancer-specific mortality, than those of other ethnic origins...
View ArticlePatient satisfaction at 24 months after treatment for localized prostate cancer
The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. While...
View ArticleThe first-line treatment of locally advanced prostate cancer (clinical stage T3)
Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy...
View ArticleProstate cancer treatment and quality of life in the “real world”
The idea that most men will recover meaningful erectile and sexual function after treatment for prostate cancer has long been disputed by many in the patient community. We now seem to have some better...
View ArticleSynergy between radiation of metastases and immunotherapy confirmed
Two clinical trials have now confirmed the abscopal or bystander effect in prostate cancer. These effects occur when cancer cells that are not directly treated are nonetheless killed. All cancer...
View ArticleThe virtual prostate cancer patient
A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient...
View ArticleOnvansertib in treatment of abiraterone-resistant mCRPC
We hear that an investigational drug called onvansertib — a so-called polo-like kinase 1 (PLK1) inhibitor — may have benefit in the treatment of men with metastatic, castration-resistant prostate...
View Article